Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials ; volume:18 ; number:1 ; day:22 ; month:9 ; year:2016 ; pages:1-13 ; date:12.2016
Arthritis Research & Therapy ; 18, Heft 1 (22.9.2016), 1-13, 12.2016
- Creator
-
Teitsma, Xavier M.
- Contributor
-
Marijnissen, Anne Karien A.
Bijlsma, Johannes W. J.
Lafeber, Floris P. J.
Jacobs, Johannes W. G.
SpringerLink (Online service)
- DOI
-
10.1186/s13075-016-1108-9
- URN
-
urn:nbn:de:1111-201610233832
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Teitsma, Xavier M.
- Marijnissen, Anne Karien A.
- Bijlsma, Johannes W. J.
- Lafeber, Floris P. J.
- Jacobs, Johannes W. G.
- SpringerLink (Online service)
Other Objects (12)
Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
Tocilizumab: A Review in Rheumatoid Arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
Tocilizumab: A Review in Rheumatoid Arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
Tocilizumab: A Review in Rheumatoid Arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab